Press Release and Management Discussion & Analysis for the Fourth Quarter ended March 31, 2026
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals reported strong Q4 FY26 results with consolidated revenue of INR 37,706 million, up 15.8% YoY. Full year FY26 revenue grew 27.5% to INR 169,825 million, driven significantly by a landmark AbbVie licensing deal for ISB 2001 worth USD 700 million upfront and potential USD 1.925 billion total. North America showed exceptional FY26 growth of 136.6% to INR 71,390 million. EBITDA margin for Q4 was 20.2% and full year 26.9%. PAT for FY26 stood at INR 13,620 million with 7.8% margin. Key launches included first generic Flovent HFA with CGT designation, RYALTRIS showing >50% growth, and differentiated products in India like GLIPIQ (semaglutide) for diabetes. The company also settled antitrust litigation for USD 29.628 million payable over 5 years.
Strong FY26 performance with 27.5% revenue growth validates Glenmark's differentiated strategy. The AbbVie deal provides significant cash infusion and validates IGI's innovation pipeline. However, India business declined 17% for the full year despite Q4 recovery, which may concern domestic-focused investors. Settlement of legal issues removes overhang.